|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
immunotherapy
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvedBy
|
gptkb:non-small_cell_lung_cancer
gptkb:cutaneous_squamous_cell_carcinoma
gptkb:urothelial_carcinoma
gptkb:biliary_tract_cancer
gptkb:cancer
gptkb:FDA
gptkb:head_and_neck_squamous_cell_carcinoma
gptkb:classical_Hodgkin_lymphoma
gptkb:microsatellite_instability-high_cancer
gptkb:primary_mediastinal_large_B-cell_lymphoma
gptkb:triple-negative_breast_cancer
2014
colorectal cancer
esophageal cancer
melanoma
hepatocellular carcinoma
gastric cancer
renal cell carcinoma
Merkel cell carcinoma
|
|
gptkbp:ATCCode
|
L01XC18
|
|
gptkbp:brand
|
gptkb:Keytruda
|
|
gptkbp:CASNumber
|
1374853-91-4
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:drugClass
|
immunotherapy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pembrolizumab
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks PD-1/PD-L1 interaction
|
|
gptkbp:molecularWeight
|
146,000 g/mol
|
|
gptkbp:monoclonalAntibodyType
|
humanized IgG4 kappa
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
pruritus
hepatitis
nephritis
hypothyroidism
rash
inflammatory bowel disease
pneumonitis
endocrinopathies
|
|
gptkbp:target
|
PD-1 protein
|
|
gptkbp:UNII
|
4Z3D8L7MBT
|
|
gptkbp:usedFor
|
gptkb:cancer
|
|
gptkbp:bfsParent
|
gptkb:NCT03400917
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|